Cost-effectiveness of the RefluxStop device for management of refractory gastroesophageal reflux disease in Switzerland.

Harper, Sam; Kartha, Muralikrishnan; Mealing, Stuart; Borbély, Yves M; Zehetner, Jörg (2024). Cost-effectiveness of the RefluxStop device for management of refractory gastroesophageal reflux disease in Switzerland. Journal of Medical Economics, 27(1), pp. 805-815. Taylor and Francis 10.1080/13696998.2024.2362564

Text Cost-effectiveness_of_the_RefluxStop_device_for_management_of_refractory_gastroesophageal_reflux_disease_in_Switzerland.pdf - Accepted Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) | Request a copy

Introduction: One of the most prevalent conditions in Western societies is gastroesophageal reflux disease (GERD). In Switzerland, the standard treatment for GERD is proton pump inhibitor (PPI)-based medical management, but surgical options such as Nissen fundoplication and the MSA system are available. RefluxStop is a novel device that offers an alternative solution. The purpose of this report is to evaluate the cost-effectiveness of RefluxStop compared to PPIs and existing surgical treatments.Methods: A model (Markov) was developed using the Swiss healthcare payer perspective with a lifetime horizon, one-month cycle length, and a 3% annual discount rate for costs and benefits. Adverse events specific to treatment arms were incorporated, and benefits were measured in quality-adjusted life-years (QALYs). Clinical efficacy data for RefluxStop was obtained from its CE mark study, and comparator treatments were based on published literature. Deterministic and probabilistic sensitivity analyses were used to explore uncertainty. Since there are no head-to-head studies between RefluxStop and PPI therapy, Nissen fundoplication, or MSA, a limitation of this study is the use of naïve, indirect comparison of clinical effectiveness between the studied treatment options.Results: Higher QALYs and lower costs were provided by RefluxStop compared to Nissen fundoplication and the LINX system. The incremental cost-effectiveness ratio (ICER) for RefluxStop was CHF 2,116 in comparison to PPI-based medical management. At a cost-effectiveness threshold of CHF 100,000 per QALY gained, the probability of RefluxStop being cost-effective was high, with probabilities of 100%, 97%, and 100% against PPI-based medical management, Nissen fundoplication, and MSA, respectively. Robustness of the analysis was provided by deterministic and probabilistic sensitivity analyses.Conclusion: This cost-effectiveness analysis demonstrates that there is a high likelihood of RefluxStop being a cost-effective treatment modality in adults with GERD when compared with other treatment options available in Switzerland.

Interest & Impact

Downloads

0 since deposited on 03 Jun 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item